TABLE 2.
Univariate and multivariate analysis for disease‐free survival of cytoplasmic CAIX protein expression and clinicopathological characteristics in ER‐negative cohort (n = 191).
| Clinicopathological characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (≤ 50/> 50 years) | 1.46 (0.95–2.25) | 0.088 | — | — |
| Tumour size (mm) (≤ 20/21–50/> 50) | 1.84 (1.29–2.61) | < 0.001* | 1.77 (1.01–3.09) | 0.045* |
| Grade (I/II/III) | 1.09 (0.72–1.65) | 0.671 | — | — |
| Involved lymph node (negative/positive) | 2.13 (1.41–3.21) | < 0.001* | 1.46 (0.72–2.94) | 0.296 |
| PR status (negative/positive) | 0.51 (0.13–2.07) | 0.344 | — | — |
| Her‐2 status (negative/positive) | 1.25 (0.82–1.91) | 0.309 | — | — |
| Ki67 index (low/high) | 0.97 (0.62–1.51) | 0.875 | — | — |
| Lymphatic vessel invasion (no/yes) | 3.18 (1.87–5.41) | < 0.001* | 3.04 (1.71–5.40) | < 0.001* |
| Blood vessel invasion (no/yes) | 2.92 (1.58–5.41) | < 0.001* | 1.76 (0.86–3.63) | 0.123 |
| Tumour necrosis (low/high) | 1.75 (1.00–3.04) | 0.048* | 2.09 (0.85–5.14) | 0.110 |
| Klintrup–Mäkinen grade (low/high) | 0.86 (0.65–1.14) | 0.291 | — | — |
| CD68+ (low/moderate/high) | 0.74 (0.54–1.02) | 0.066 | — | — |
| CD8+ (low/moderate/high) | 0.62 (0.45–0.85) | 0.003* | 0.73 (0.50–1.05) | 0.089 |
| CD138+ (low/moderate/high) | 1.28 (0.95–1.72) | 0.111 | — | — |
| Tumour stroma percentage (low/high) | 1.96 (1.30–2.95) | 0.001* | 2.46 (1.21–4.99) | 0.013* |
| Tumour budding (low/high) | 1.97 (1.27–3.06) | 0.002* | 1.19 (0.61–2.29) | 0.611 |
| Adjuvant chemotherapy (no/yes) | 0.89 (0.59–1.37) | 0.622 | — | — |
| Adjuvant radiotherapy (no/yes) | 1.16 (0.77–1.75) | 0.480 | — | — |
| Cytoplasmic CAIX (low/high) | 1.54 (1.01–2.33) | 0.041* | 1.99 (1.07–3.71) | 0.029* |
*Statistically significant p value < 0.05.